Increases in sGFAP during BCDT are linked to disability progression in MS, independent of relapse activity. sGFAP is a stronger predictor of disease progression than sNfL, reflecting different ...

A major international Phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab—a medication already prescribed to some patients with MS—significantly slows ...

Higher consumption of oily fish such as tuna and salmon or lean fish like cod and perch is associated with a reduced risk for disability progression in patients with multiple sclerosis (MS), a new ...

Feb. 25 (UPI) --A diet rich in fish may help slow down the progression of the incurable, often disabling autoimmune disease of multiple sclerosis, according to new, long-term Swedish study published ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He's also a ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various associated neurological symptoms, ranging from vision problems to numbness, ...

Add Yahoo as a preferred source to see more of our stories on Google. The smartphone app showed it was able to track certain digital biomarkers in MS patients. Credit: daily_creativity / ...

Panelists discuss how economic models must account for the broader impact of MS progression on earning potential, family planning, caregiver burden, and quality of life rather than focusing solely on ...

Multiple sclerosis (MS)is a progressive disease of the central nervous system that can cause symptoms throughout the body, including both physical and cognitive symptoms. Obesity in childhood and ...

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows ...